Suppr超能文献

胰腺癌全胰切除术的结果。

Results of total pancreatectomy for adenocarcinoma of the pancreas.

作者信息

Karpoff H M, Klimstra D S, Brennan M F, Conlon K C

机构信息

Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.

出版信息

Arch Surg. 2001 Jan;136(1):44-7; discussion 48. doi: 10.1001/archsurg.136.1.44.

Abstract

HYPOTHESIS

Total pancreatectomy for infiltrating ductal adenocarcinoma is not superior to pancreaticoduodenectomy or distal pancreatectomy.

DESIGN

A retrospective analysis of a prospective database of patients.

SETTING

Memorial Sloan-Kettering Cancer Center, New York, NY.

PATIENTS

All patients (n = 488) undergoing pancreatic resection.

MAIN OUTCOME MEASURES

Duration of operation, estimated blood loss, complications, length of stay, number of positive lymph nodes, presence of a positive margin, and survival times were analyzed.

RESULTS

Thirty-five patients were identified who underwent total pancreatectomy, 28 of whom had adenocarcinoma. Median length of stay was 32 days; 19 (54%) developed postoperative complications, of which 63% were infectious. Thirty-day mortality was 3% (1 patient). Median survival was 9.3 months (range, 0.6-172 months). There was no significant difference between patients with and without adenocarcinoma in terms of duration of operation, estimated blood loss, complications, length of stay, or number of readmissions. In patients with adenocarcinoma, margin or nodal status were not significant survival variables. Patients undergoing total pancreatectomy for adenocarcinoma had a significantly worse overall survival than those undergoing total pancreatectomy for other reasons (P<.001), or compared with a contemporaneous cohort with adenocarcinoma undergoing pancreaticoduodenectomy (n = 409) and distal pancreatectomy (n = 51) (7.9 vs 17.2 months; P<.002).

CONCLUSIONS

Total pancreatectomy can be performed safely with low mortality; survival is predicted by the underlying pathologic findings: patients undergoing total pancreatectomy for adenocarcinoma have a uniformly poor outcome. Those undergoing total pancreatectomy for benign disease or nonadenocarcinoma variants can have long-term survival. In patients who require total pancreatectomy for ductal adenocarcinoma, the survival is so poor as to bring into question the value of the operation.

摘要

假设

对于浸润性导管腺癌,全胰切除术并不优于胰十二指肠切除术或远端胰腺切除术。

设计

对前瞻性患者数据库进行回顾性分析。

地点

纽约州纽约市纪念斯隆-凯特琳癌症中心。

患者

所有接受胰腺切除术的患者(n = 488)。

主要观察指标

分析手术时长、估计失血量、并发症、住院时间、阳性淋巴结数量、切缘阳性情况及生存时间。

结果

确定35例接受全胰切除术的患者,其中28例患有腺癌。中位住院时间为32天;19例(54%)发生术后并发症,其中63%为感染性并发症。30天死亡率为3%(1例患者)。中位生存期为9.3个月(范围:0.6 - 172个月)。腺癌患者与非腺癌患者在手术时长、估计失血量、并发症、住院时间或再入院次数方面无显著差异。在腺癌患者中,切缘或淋巴结状态不是显著的生存变量。因腺癌接受全胰切除术的患者总体生存率明显低于因其他原因接受全胰切除术的患者(P <.001),或与同期接受胰十二指肠切除术(n = 409)和远端胰腺切除术(n = 51)的腺癌队列相比(7.9个月对17.2个月;P <.002)。

结论

全胰切除术可安全进行,死亡率低;生存情况由潜在病理结果预测:因腺癌接受全胰切除术的患者预后普遍较差。因良性疾病或非腺癌变体接受全胰切除术的患者可长期生存。对于因导管腺癌需要进行全胰切除术的患者,生存率极低,以至于该手术的价值受到质疑。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验